WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.

Raccontata dabiopharmadive.comcnbc.comfiercepharma.com

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
cnbc.comStai leggendo10 h fa

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.

originale
fiercepharma.com9 h fa

ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone

For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral GLP-1 for obesity—marked an opportunity to recapture some of the ch | For Novo Nordisk,…

Leggi questa versione → originale

Timeline cronologica

  1. lunedì 8 giugno 2026·biopharmadive.com

    ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

    At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

  2. lunedì 8 giugno 2026·cnbc.com

    Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

    Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.

biopharmadive.com1 g fa

ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

Leggi questa versione → originale
  • lunedì 8 giugno 2026·fiercepharma.com

    ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone

    For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral GLP-1 for obesity—marked an opportunity to…